Work

Combining VEGF receptor inhibitors and angiotensin-(1–7) to target renal cell carcinoma

Year: 2021

Type: editorial

Abstract: Resistance to tyrosine kinase inhibitors of the vascular endothelial growth factor receptor inevitably develops in most patients with metastatic kidney cancer. Our recent findings demonstrate that addition of angiotensin-(1-7) peptide can be a potential therapy that delays such resistance.

Source: Molecular & Cellular Oncology

DOI: 10.1080/23723556.2021.1918529

Authors: Thomas Walther, Prateek Khanna, Rupal S. Bhatt

Institutions: University College Cork, Universitätsmedizin Greifswald, Mount Auburn Hospital, Beth Israel Deaconess Medical Center, Harvard University

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $1,590

OpenAlex ID: W3172555426

Cites: 8

Cited by: 3

Related to: 10